Konstantia Kantartzi

Dr. Konstantia Kantartzi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ESElisavet Stavropoulou
Elisavet Stavropoulou
KKKonstantia Kantartzi
Konstantia Kantartzi
Christina TsigalouChristina Tsigalou
Christina Tsigalou
Theocharis G KonstantinidisTheocharis G Konstantinidis
Theocharis G Konstantinidis
GRGioulia Romanidou
Gioulia Romanidou
EBEugenia Bezirtzoglou
Eugenia Bezirtzoglou
The recent new developments in technology with culture-independent techniques including genome sequencing methodologies shed light on the identification of microbiota bacterial species and their role in health and disease. Microbiome is actually reported as an important predictive tool for evaluating characteristic shifts in case of disease. Our present review states the development of different renal diseases and pathologies linked to the intestinal dysbiosis, which impacts on host homeostasis. The gastrointestinal–kidney dialogue provides intriguing features in the pathogenesis of several renal diseases. Without any doubt, investigation of this interconnection consists one of the most cutting-edge areas of research with potential implications on our health.

3 March 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
EUGENIA BEZIRTZOGLOUEUGENIA BEZIRTZOGLOU
EUGENIA BEZIRTZOGLOU
Elisavet StavropoulouElisavet Stavropoulou
Elisavet Stavropoulou
KKKonstantia Kantartzi
Konstantia Kantartzi
Christina TsigalouChristina Tsigalou
Christina Tsigalou
CVChrysoula (Chrysa) Voidarou
Chrysoula (Chrysa) Voidarou
Yiannis KourkoutasYiannis Kourkoutas
Yiannis Kourkoutas
Over the last decades, the incidence of diabetes has increased in developed countries and beyond the genetic impact, environmental factors, which can trigger the activation of the gut immune system, seem to affect the induction of the disease process. Since the composition of the gut microbiome might disturb the normal interaction with the immune system and contribute to altered immune responses, the restoration of normal microbiota composition constitutes a new target for the prevention and treatment of diabetes. Thus, the interaction of gut microbiome and diabetes, focusing on mechanisms connecting gut microbiota with the occurrence of the disorder, is discussed in the present review. Finally, the challenge of functional food diet on maintaining intestinal health and microbial flora diversity and functionality, as a potential tool for the onset inhibition and management of the disease, is highlighted by reporting key animal studies and clinical trials. Early onset of the disease in the oral cavity is an important factor for the incorporation of a functional food diet in daily routine.

19 March 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ESElisavet Stavropoulou
Elisavet Stavropoulou
KKKonstantia Kantartzi
Konstantia Kantartzi
Christina TsigalouChristina Tsigalou
Christina Tsigalou
KAKonstantina Aftzoglou
Konstantina Aftzoglou
CVChrysa Voidarou
Chrysa Voidarou
EBEugenia Bezirtzoglou
Eugenia Bezirtzoglou
The gut microbiome is known as an important predictive tool for perceiving characteristic shifts in disease states. Multiple renal diseases and pathologies seem to be associated with gut dysbiosis which directly affects host homeostasis. The gastrointestinal-kidney dialogue confers interesting information about the pathogenesis of multiple kidney diseases. Moreover, aging is followed by specific shifts in the human microbiome, and gradual elimination of physiological functions predisposes the microbiome to inflammaging, sarcopenia, and disease. Aging is characterized by a microbiota with an abundance of disease-associated pathobionts. Multiple factors such as the immune system, environment, medication, diet, and genetic endowment are involved in determining the age of the microbiome in health and disease. Our present review promotes recently acquired knowledge and is expected to inspire researchers to advance studies and investigations on the involved pathways of the gut microbiota and kidney axis.

26 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GAGeorgios Aletras
Georgios Aletras
MBMaria Bachlitzanaki
Maria Bachlitzanaki
MSMaria Stratinaki
Maria Stratinaki
ELEmmanuel Lamprogiannakis
Emmanuel Lamprogiannakis
SPStylianos Panagoutsos
Stylianos Panagoutsos
KSKostas Stylianou
Kostas Stylianou
Introduction: Acute cardiorenal syndrome (ACRS) is a common complication of acute heart failure (AHF), leading to worse outcomes and therapeutic challenges. This study aimed to identify clinical parameters associated with ACRS and evaluate its impact on prognosis in hospitalized AHF patients. Methods: This prospective observational study included patients hospitalized for AHF at the Venizelio Cardiology Department from February to November 2023. Demographic characteristics, comorbidities, medications, laboratory and echocardiographic parameters, hospital stay, and in-hospital mortality were recorded. Patients with incomplete data or end-stage chronic kidney disease (CKD) were excluded. Survivors were followed for six months to assess renal function changes, readmissions, initiation of renal replacement therapy (RRT), and mortality. ACRS was defined as a serum creatinine increase of ≥0.3 mg/dL or ≥1.5 times baseline. Results: Among 218 hospitalized AHF patients, 112 (51.3%) developed ACRS. These patients were older, had higher CKD prevalence, worse New York Heart Association (NYHA) functional class, lower hemoglobin, and higher N-terminal Pro-B-type Natriuretic peptide (NT-proBNP) levels. Multivariate analysis identified CKD stage (OR 2.30, 95% CI 1.64–3.23, p < 0.001) and creatinine change on admission (OR 3.53, 95% CI 2.02–6.18, p < 0.001) as independent predictors of ACRS. ACRS was associated with higher in-hospital mortality, longer hospital stays, increased vasoactive medication use, worsening renal function, and higher six-month all-cause readmission and mortality rates. Conclusions: ACRS is a frequent and severe complication in AHF. CKD stage and creatinine on admission are key predictors. Early recognition for risk stratification and individualized management are crucial to improving outcomes in this high-risk population.

Verified
Journal Article
Open access
PDF file
GRGioulia Romanidou
Gioulia Romanidou
Theocharis G KonstantinidisTheocharis G Konstantinidis
Theocharis G Konstantinidis
ANAnastasia-Maria Natsi
Anastasia-Maria Natsi
KKKonstantia Kantartzi
Konstantia Kantartzi
Maria PanopoulouMaria Panopoulou
Maria Panopoulou
IMIoannis Mitroulis
Ioannis Mitroulis
HELLP (Hemolysis, Elevated Liver enzymes and Low Platelets) syndrome is a life-threatening complication of pregnancy, which is often secondary to preeclampsia. To date, there is no biomarker in clinical use for the early stratification of women with preeclampsia who are under increased risk of HELLP syndrome. Herein, we show that the levels of circulating developmental endothelial locus-1 (DEL-1), which is an extracellular immunomodulatory protein, are decreased in patients with HELLP syndrome compared to preeclampsia. DEL-1 levels are also negatively correlated with the circulating levels of kidney injury molecule-1 (KIM-1), which is a biomarker for disorders associated with kidney damage. Receiver-operating characteristic curve analysis for DEL-1 levels and the DEL-1 to KIM-1 ratio demonstrates that these values could be used as a potential biomarker that distinguishes patients with HELLP syndrome and preeclampsia. Finally, we show that placental endothelial cells are a source for DEL-1, and that the expression of this protein in placenta from patients with HELLP syndrome is minimal. Taken together, this study shows that DEL-1 is downregulated in HELLP syndrome both in the circulation and at the affected placental tissue, suggesting a potential role for this protein as a biomarker, which must be further evaluated.

Verified
Journal Article
Open access
PDF file
TTTheodoros Tourountzis
Theodoros Tourountzis
GLGeorge Lioulios
George Lioulios
SSStamatia Stai
Stamatia Stai
SLSteven Van Laecke
Steven Van Laecke
EMELENI MOYSIDOU
ELENI MOYSIDOU
MSMaria Stangou
Maria Stangou
The impact of protein bound uremic toxins (PBUTs) and lymphocyte alterations in morbidity and mortality in patients on hemodialysis (HD) is of great concern. The aim of this study was the assessment of association between PBUTs, immunosenescent lymphocytes’ phenotype and clinical events [cardiovascular, severe infections (hospitalization due to infection, respiratory infection), all-cause mortality] during 2-year follow-up. In this prospective observational study, lymphocytes’ phenotype of 54 patients on HD and 31 age-matched controls was analyzed by flow cytometry, and simultaneously, PBUT serum levels [hippuric acid (HA), indoxyl sulfate (IxS), p-cresyl sulfate (pCS), p-cresyl glycuronide (pCG), in-dole-3-acetic acid (IAA), and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF)] were quantified by ultra-performance liquid chromatography. Patients with increased levels of free IxS and total and free HA had higher mortality within a 2-year follow-up period (p = 0.049, p = 0.01, p = 0.01, respectively). In patients who experienced cardiovascular events, higher concentrations of CMPF (p = 0.015) were observed. Higher total and free HA levels associate with increased all-cause mortality in patients on HD, independently of age, dialysis vintage, and decreased count of CD4+CD45RA+CD31+ and naïve B cells (CD19+IgD+CD27−). In patients on HD, increased levels of total and free HA associate with an increased risk of death.